Inclusion Criteria:

1. Histologically proven diffuse large B-cell lymphoma in first relapse after CR, less
than PR or PR to first line treatment De Novo DLBCL, DLBCL arising from transformed
follicular lymphoma or chronic lymphocytic leukaemia are allowed.

Prior rituximab is allowed Prior radiation is allowed Prior autologous stem cell
transplant is allowed CD20 negative relapses are allowed

2. Age between 21-70

3. Written informed consent

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

5. Minimum life expectancy of 3 months

6. Previously treated with chemotherapy containing anthracyclines and rituximab

7. Negative urine or serum pregnancy test on females of childbearing potential

8. Female subject is either post-menopausal or surgically sterilized or willing to use
an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine
device, diaphragm with spermicide, condom with spermicide, or abstinence) for the
duration of the study.

9. Male subject agrees to use an acceptable method for contraception for the duration of
the study.

10. No CNS involvement

11. Measurable disease on CT scan by international working group response criteria

Exclusion Criteria:

1. Prior allogeneic transplantation

2. Prior treatment with bortezomib

3. Concomitant use of any other anti-cancer therapy

4. Concomitant use of any other investigational agent

5. Known infection with human immunodeficiency virus (HIV)

6. Patient has known clinically active hepatitis B (carriers of hepatitis B are
permitted to enter the study)

7. Contraindication to any drug contained in chemotherapy regimens

8. Not previously treated with anthracycline-containing regimens

9. Impaired liver, renal or other organ function not caused by lymphoma, which will
interfere with the treatment schedule

10. Poor bone marrow reserve (neutrophils <1.0 x 109/L or platelets <75 x 10(9)/L unless
related to bone marrow infiltration

11. Subject has a calculated or measured creatinine clearance of <20 mL/minute within 14
days before enrollment.

12. Myocardial infarction within 6 months prior to enrollment or has New York Hospital
Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia or active conduction system abnormalities. Prior to study entry, any ECG
abnormality at Screening has to be documented by the investigator as not medically
relevant.

13. Clinically significant active infection

14. Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before
enrollment.

15. Patients who are pregnant or breast-feeding

16. Coexistent second malignancy or history of prior malignancy within previous 3 years
(excluding non-melanoma skin tumors or in situ carcinoma of the cervix)

17. Any significant medical or psychiatric condition that might prevent the patient from
complying with all study procedures.